Company / Capital Expenditures
Beam Therapeutics Inc. Capital Expenditures History
FY2019-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Capital Expenditures
$14.9M
FY2025
5-year range
$8.9M / $49.0M
FY2021-FY2025
Trend
+67.1%
vs FY2024
Sector context
#48 of 194
Health Care
What the data says
Beam Therapeutics Inc.'s capital expenditures of $15M is higher than 75% of companies in the Health Care sector (FY2025). Capital Expenditures returned to growth in FY2025 after 2 years of decline, reaching $15M.
Based on SEC 10-K filings.
$15M in FY2025 with a 5-year CAGR of +3.6%. Top quartile in the Health Care sector.
Declined from $34M to $15M over the past 2 years.
Health Care sector context is included.
Capital Expenditures over time
Growth rates
- 3-Year CAGR
- -32.7%
- 5-Year CAGR
- +3.6%
- 10-Year CAGR
- -
Sector benchmark
-87.3% below sector average
Key checks
Key Insights
- 5-year CAGR of +3.6%, indicating consistent growth.
- In FY2025, capital expenditures increased 67.1% year-over-year.
- Ranks #48 out of 194 companies in the Health Care sector.
- Peak capital expenditures was recorded in FY2022.
Company context
Key Data Points
- Altman Z-Score 1.06 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Capital ExpendituresValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $14.9M | +67.1% |
| FY2024 | $8.9M | -73.5% |
| FY2023 | $33.7M | -31.1% |
| FY2022 | $49.0M | +4.6% |
| FY2021 | $46.8M | +273.9% |
| FY2020 | $12.5M | +0.0% |
| FY2019 | $12.5M | - |
As of FY2025 · SEC 10-K · Updated Jul 2, 2026